Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SNOA 
Sonoma Pharmaceuticals Inc (SNOA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: SNOA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.4
1 Year Target Price $13.4
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.73% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.90M USD | Price to earnings Ratio - | 1Y Target Price 13.4 |
Price to earnings Ratio - | 1Y Target Price 13.4 | ||
Volume (30-day avg) 1 | Beta 1.4 | 52 Weeks Range 1.75 - 6.92 | Updated Date 09/17/2025 |
52 Weeks Range 1.75 - 6.92 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -23.84% | Operating Margin (TTM) -27.27% |
Management Effectiveness
Return on Assets (TTM) -16.06% | Return on Equity (TTM) -78.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3971713 | Price to Sales(TTM) 0.46 |
Enterprise Value 3971713 | Price to Sales(TTM) 0.46 | ||
Enterprise Value to Revenue 0.27 | Enterprise Value to EBITDA -0.17 | Shares Outstanding 1643260 | Shares Floating 1622330 |
Shares Outstanding 1643260 | Shares Floating 1622330 | ||
Percent Insiders 1.23 | Percent Institutions 6.31 |
Upturn AI SWOT
Sonoma Pharmaceuticals Inc
Company Overview
History and Background
Sonoma Pharmaceuticals, Inc. (SNOA) was founded in 1998. Initially focused on stabilized hypochlorous acid (HOCl) solutions, the company has evolved into a specialty pharmaceutical company focused on developing and commercializing products for dermatological conditions, wound care, and eye care. They have gone through multiple name and strategic changes over time.
Core Business Areas
- Dermatology: Focuses on developing and commercializing products for skin conditions, including acne, eczema, and psoriasis. This includes prescription and OTC products.
- Wound Care: Develops and sells products designed to promote wound healing and prevent infection in acute and chronic wounds.
- Eye Care: Offers products focused on improving eye health and treating eye-related conditions.
Leadership and Structure
The leadership team includes Amy Trombly as CEO, and other key personnel in finance, operations, and research & development. Sonoma is a publicly traded company with a board of directors overseeing its operations.
Top Products and Market Share
Key Offerings
- Microcynu00ae Technology: Microcyn is Sonoma's proprietary technology platform that stabilizes hypochlorous acid (HOCl). Products based on Microcyn are used for wound care, dermatology, and eye care. Sonoma has various partnerships to market Microcyn globally. Market share data is difficult to obtain as distribution is fragmented and through partnerships, however Microcyn is a recognized brand in advanced wound care. Competitors include companies offering similar wound care solutions using alternative technologies, such as Convatec and Smith & Nephew. Revenue generated from this product line makes up the majority of the overall revenue.
- Ceramax Technology: Ceramax is Sonoma's platform which includes antimicrobial barrier creams and lotions. Competitors include generic OTC creams, big Pharma creams and smaller specialty pharmaceutical companies.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with ongoing research and development activities. Sonoma competes within the dermatology, wound care, and eye care segments, which are driven by aging populations, rising healthcare costs, and increasing awareness of treatment options. There is increased competition through online channels and access to generic medications.
Positioning
Sonoma positions itself as a developer of advanced wound care and dermatology solutions using stabilized hypochlorous acid technology. Their competitive advantage lies in the unique properties of Microcynu00ae technology and its proven efficacy in various applications.
Total Addressable Market (TAM)
The total addressable market for wound care, dermatology, and eye care is significant and growing. Estimates exceed tens of billions of dollars globally. Sonoma's ability to penetrate and expand within these markets will depend on its product development, marketing strategies, and partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary Microcynu00ae technology
- Established partnerships for global distribution
- Focus on niche markets within dermatology, wound care, and eye care
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on partnerships for sales and marketing
- Small scale limits access to markets
Opportunities
- Expanding product portfolio through research and development
- Acquiring new technologies or companies
- Reaching new geographic markets
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes and compliance requirements
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- VRX
- JNJ
- PFE
Competitive Landscape
Sonoma is a smaller player compared to the competitors. Its competitive advantage lies in specialized product lines. The much bigger competitors compete through diversified product offerings and large economies of scale.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on financial performance over the past several years. Recent performance has been variable.
Future Projections: Future projections require analyst estimates. Please refer to financial news providers for future growth.
Recent Initiatives: Recent initiatives include expanded collaborations and distribution agreements.
Summary
Sonoma Pharmaceuticals, Inc. is a small company focused on developing and commercializing dermatology and wound care solutions. Its strengths lie in its Microcyn technology, but its limited resources and reliance on partnerships present challenges. The company needs to strategically leverage its technology and expand its market reach to achieve sustainable growth, while facing competition from larger pharmaceutical firms.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports (assumptions based on limited availability)
Disclaimers:
The data provided is for informational purposes only and does not constitute investment advice. Market share data is estimated. Please conduct thorough research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sonoma Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2007-01-25 | CEO, President & Director Ms. Amy M. Trombly Esq., J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 8 | Website https://sonomapharma.com |
Full time employees 8 | Website https://sonomapharma.com | ||
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.